Pregnancy Outcomes After Endometrioma Excision in Patients Undergoing *In Vitro* Fertilization and Embryo Transfer: A Historical Cohort Study

Rubin Raju, MD, Komal Agarwal, MD, Omar Abuzeid, MD, Salem Joseph, BS, Mohammed Ashraf, MD, and Mostafa I. Abuzeid, MD

**Abstract**

**Objective:** The objective of the study was to examine the effect of endometrioma excision on pregnancy outcomes in women with advanced-stage endometriosis who underwent *in vitro* fertilization and embryo transfer (IVF-ET).

**Design:** This is a historical cohort study.

**Materials and Methods:** We compared the pregnancy outcomes of 141 women undergoing IVF-ET. The study group consisted of 25 patients who had stage III/IV endometriosis and endometrioma excision (group 1). The control groups included 40 patients who had stage III/IV endometriosis, but no endometrioma and who underwent ovariolysis (group 2) and 76 patients with tubal factors infertility who underwent tubal surgery (group 3). After surgery up to two IVF-ET cycles in each group were analyzed.

**Results:** Our study showed that the mean total dose of gonadotropin administered in IVF-ET cycle I was higher in group 1 compared with groups 2 and 3 (*p* = 0.03). Otherwise, there was no significant difference in the ovarian responses among the three groups. There was a statistically significant increase in clinical pregnancy rate per cycle in the endometrioma group (69.7%) versus the ovariolysis group (48.1%) and tubal factor group (48.0%). However, there was no significant difference in delivery rate per cycle among the three groups. There was a statistically significant higher miscarriage rate in the endometrioma group (39.1%) compared with the ovariolysis group (11.5%) and tubal factor group (14.3%).

**Conclusion:** In conclusion, our study suggests that endometrioma excision surgery does not compromise the overall ovarian reserve or pregnancy outcomes after IVF-ET. (J GYNECOL SURG 31:214)

**Introduction**

**Endometriosis is a benign disease** characterized by the presence of endometrial glands and stroma outside the uterus. Its overall prevalence among reproductive age women is estimated to be between 3% and 10%, but it affects between 20% and 40% of infertile women. Endometriomas affect 17%–44% of women with endometriosis. The origin of ovarian endometrioma is unknown; however, it is generally believed that they result initially from a deposit of endometrium passed through the fallopian tube, causing adherence of the ovary to the pelvic peritoneum and progressive invagination of the ovarian cortex.

Endometriomas are associated with increased oxidative stress and vascular compromise that can cause damage to ovarian reserve and function. Controversy exists with respect to their management. Surgical resection of endometriomas is widely practiced to overcome infertility, due to poor response to medical therapy, but this practice is not yet supported by solid evidence. A risk of surgical removal of ovarian endometrioma is the inadvertent loss of normal ovarian tissue. There are studies that suggest that excision of endometriomas is associated with a reduction in anti-müllian hormone (AMH) levels, suggestive of a decrease in ovarian reserve, which can have significant implications on fertility outcomes.

The purpose of this study was to examine the effect of endometrioma excision on pregnancy outcomes in women with advanced-stage endometriosis undergoing *in vitro* fertilization and embryo transfer (IVF-ET).
Materials and Methods

This is a historical cohort study using a retrospective chart review and a database from the years 1991 to 2009 of infertile patients who presented to our unit. The study was approved by the Institutional Review Board at Hurley Medical Center, Michigan Flint.

A total of 141 patients were included in our study. The inclusion criteria for the study group (group 1) were infertile patients undergoing IVF-ET with stage III/IV endometriosis and a history of unilateral or bilateral laparoscopic endometrioma excision (n=25). The diagnosis of endometriosis was histologically confirmed. The control groups included patients who had stage III/IV endometriosis but no endometrioma who underwent ovariolysis and (group 2, n=40) and patients with tubal factors infertility who underwent tubal surgery (group 3, n=76).

Group 3 consisted of patients with no laparoscopic evidence of endometriosis who underwent tubal surgery for tubal factor infertility, failed to conceive, and, subsequently, underwent IVF-ET.

The operative laparoscopy and IVF-ET were performed by the same group of infertility specialists (Mostafa I. Abuzeid and Mohammed Ashraf) under similar operative setting in all patients. The same surgical techniques were applied in all patients. When suspicious spots of endometriosis were found anywhere in the pelvis, in the majority of cases, argon beam coagulator (Birchert Medical System, Irvine, CA) was used to ablate the spots seen. If endometriosis was found on the pelvic sidewall near the ureter, on the bladder or bowels, Argon beam coagulator was also used with extra care to avoid injury to such vital organs. Salpingo-ovarolysis was performed using blunt dissection of the ovary from the pelvic sidewall, and scissors and/or monopolar diathermy needle tip (Elmed, Chicago, IL) and Teflon probe (Elmed) to excise the sidewall, and scissors and/or monopolar diathermy needle tip (Elmed, Chicago, IL) and Teflon probe (Elmed) to excise the scar tissue from the tubes and ovaries. If endometrioma more than 1 cm was found, excision of the cyst wall was done and reconstruction of the ovarian cortex was performed with one or two interrupted sutures using 3-0 Vicryl. If an endometrioma of less than 1 cm was found, it was opened, evacuated, and the lining was ablated with the argon beam coagulator. If fimbrial phimosis or hydrosalpinges were found, fimbrioplasty or salpingostomy was performed, respectively, as previously described by our group. Starting in 1999, temporary ovarian suspension was performed for advanced endometriosis in an attempt to reduce the risk of recurrence of adhesions between ovarian fossa and ovaries as previously described by our group.

All patients underwent controlled ovarian stimulation (COS) using mid luteal downregulation protocol with GnRH-agonist or antagonist protocol and gonadotropin. The starting dose of gonadotropin was determined based on a woman’s age, body mass index, antral follicle count at baseline trans-vaginal ultrasonography, and day 3 follicle-stimulating hormone (FSH). Ovarian response was monitored with frequent serum E2 levels and trans-vaginal ultrasonography.

The criterion for human chorionic gonadotropin (HCG) administration was the presence of three or more follicles that were 17 mm in diameter. Cycle cancellation due to poor ovarian response was undertaken when less than three follicles developed. Oocyte retrieval was carried out under modified general anesthesia using trans-vaginal ultrasound (US) guided puncture of follicles at 36 hours after HCG administration. Standard procedures were carried out for the gamete–embryo handling, and ET was performed in all cases using the Wallace catheter. In the period between 1991 and 2001, ET was performed on day 3 after oocyte retrieval. During the last 7 years, ET was performed on day 5.

Embryos were graded on day 2 based on blastomere nuclear scoring and their morphologic appearance on day 3 cleavage embryos. On day 3, if six to eight embryos were of good quality, the transfer was delayed until day 5; otherwise, the embryos were transferred on day 3. Blastocysts were graded according to Gardner’s criteria. Ultrasound-guided ET was performed on either day 3 or 5. Usually, two top-quality embryos/blastoscytcs were transferred. Extra good-quality blastocystcs were frozen. Luteal phase support was the same in all groups. Over the years, different forms of vaginal progesterone were used; however, the principal remained the same. Starting on the second day after retrieval: Progesterone vaginal suppositories T.I.D., progesterone vaginal cream once a day (Crinone 8% Vaginal Gel; Watson Pharmaceuticals, Morristown, NJ) or progesterone vaginal tablets T.I.D. (Endometrin 100 mg Vaginal Insert; Ferring Pharmaceuticals, Inc., Parsippany, NJ) and progesterone in oil 100 mg I.M. every other day (Progestone in Oil 50 mg/mL Vial; Watson Laboratories, Inc., Corona, CA) were used. Since the year 2005, Estradiol B.I.D. (Estrace 2 mg; Warner Chilcott LLC, Rockaway, NJ) were also utilized for luteal phase support. If pregnancy occurred, the same treatment continued until 6 week of gestation. At that time, Estrace and Progestrone in Oil were discontinued, and vaginal progesterone was continued until 12 week of gestation.

Pregnancy was confirmed by measurement of β-HCG at 12 days after blastocyst transfer, or 14 days if ET was done on day 3. Biochemical pregnancy was defined as a transit rise in β-HCG, or a positive pregnancy test in the absence of US scan evidence of pregnancy. Clinical pregnancy was defined as the presence of a gestational sac on trans-vaginal US scan at 6 week of gestation. Miscarriage was defined as a clinical pregnancy that ended in pregnancy loss before 12 weeks of gestation. Delivery was verified by a phone call to the patient.

Up to two IVF-ET cycles after surgery were analyzed. The outcomes studied were as follows: pregnancy rate per cycle, pregnancy rate per patient, delivery rate per cycle, delivery rate per patient, and miscarriage rate. Statistical analyses were performed using Student’s t-test, chi-square test (continuous and dichotomous variables, respectively).

### Table 1. Demographic Data

<table>
<thead>
<tr>
<th>Group</th>
<th>Endometrioma excision, n=25</th>
<th>Ovaryolysis, n=40</th>
<th>Tubal group, n=76</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>34.3±4.1</td>
<td>33.1±3.9</td>
<td>32.1±3.2</td>
</tr>
<tr>
<td>Duration of infertility</td>
<td>2.6±1.7</td>
<td>3.7±3.4</td>
<td>4.0±3.5</td>
</tr>
<tr>
<td>Primary infertility (%)</td>
<td>68</td>
<td>59</td>
<td>49.4</td>
</tr>
<tr>
<td>Septal surgery (%)</td>
<td>28</td>
<td>17.5</td>
<td>17.3</td>
</tr>
</tbody>
</table>
Table 2. Variables in IVF-ET Cycle I

<table>
<thead>
<tr>
<th>Variables</th>
<th>Endometrioma excision, group 1 (n=25)</th>
<th>Ovariolysis, group 2 (n=40)</th>
<th>Tubal group, group 3 (n=76)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Days till HCG</td>
<td>10.4±1.6</td>
<td>11.0±1.4</td>
<td>11.0±1.9</td>
</tr>
<tr>
<td>Total dose of gonadotropin administered (I.U.)*</td>
<td>3825.0±1473.5</td>
<td>3101.6±1185.1</td>
<td>3071.8±1269.6</td>
</tr>
<tr>
<td>No. of mature follicles</td>
<td>8.5±4.4</td>
<td>10.3±5.6</td>
<td>9.8±4.9</td>
</tr>
<tr>
<td>Estrogen level (pg/mL)</td>
<td>2062.4±813.3</td>
<td>2230.0±1068.5</td>
<td>2072.9±1102.7</td>
</tr>
<tr>
<td>Progesterone level (ng/mL)</td>
<td>0.9±0.4</td>
<td>1.1±0.6</td>
<td>1.0±0.8</td>
</tr>
<tr>
<td>No. of mature eggs</td>
<td>9.2±4.4</td>
<td>10.0±5.5</td>
<td>10.7±5.7</td>
</tr>
<tr>
<td>No. of fertilized eggs</td>
<td>7.5±4.4</td>
<td>7.6±4.7</td>
<td>8.6±5.4</td>
</tr>
<tr>
<td>No. of embryos transferred</td>
<td>3.2±1.2</td>
<td>3.1±1.3</td>
<td>3.0±1.3</td>
</tr>
</tbody>
</table>

*p=0.03.

HCG, human chorionic gonadotropin; IVF-ET, in vitro fertilization and embryo transfer.

Table 3. Variables in IVF-ET Cycle II

<table>
<thead>
<tr>
<th>Variables</th>
<th>Endometrioma excision, group 1 (n=8)</th>
<th>Ovariolysis, group 2 (n=14)</th>
<th>Tubal group, group 3 (n=26)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Days till HCG</td>
<td>10.5±1.4</td>
<td>10.5±1.5</td>
<td>10.9±1.85</td>
</tr>
<tr>
<td>Total medication administered</td>
<td>4219±548</td>
<td>3081.7±1299</td>
<td>3305±1431</td>
</tr>
<tr>
<td>No. of mature follicles</td>
<td>7±2.2</td>
<td>10.7±6.5</td>
<td>9.15±3.8</td>
</tr>
<tr>
<td>Estrogen level</td>
<td>1834±103.1</td>
<td>2282.5±1173</td>
<td>2175.4±968</td>
</tr>
<tr>
<td>Progesterone level</td>
<td>1.0±0.4</td>
<td>1.0±0.8</td>
<td>1.2±0.6</td>
</tr>
<tr>
<td>No. of mature eggs</td>
<td>8.6±3.7</td>
<td>10.5±6.9</td>
<td>10.4±3.3</td>
</tr>
<tr>
<td>No. of fertilized eggs</td>
<td>6.0±1.6</td>
<td>8.5±6.3</td>
<td>8.0±4.1</td>
</tr>
<tr>
<td>No. of embryos transferred</td>
<td>3.5±1.1</td>
<td>3.7±1.7</td>
<td>3.3±1.7</td>
</tr>
</tbody>
</table>

Miscarriage rate was significantly higher in group 1 compared with groups 2 and 3 (39.1% vs. 11.5% and 14.3% respectively; p-value<0.003). There was no significant difference in the delivery rate per cycle and delivery rate per patient among the three groups (Table 4).

Discussion

The appropriate management of endometriomas in women suffering from subfertility is still a topic of debate. Several surgical techniques have been described. Most involve opening and draining the cyst followed by either excision using the stripping technique or ablation of the cyst wall with electrocautery or CO2 laser.14 Due to a high recurrence rate, drainage alone is not recommended.17 A Cochrane review found that excisional surgery provides better outcomes than ablative surgery.18 Donnez et al. (2010) described a combined technique using both excision and ablation to minimize ovary damage and recurrence rates.19

The main concern with surgery is the associated inadvertent removal of ovarian parenchyma that can have a significant impact on ovarian reserve. Muzii et al. showed that the stripping technique removes ovarian tissue in about 54% of cases.20 A significant reduction in ovarian reserve has also been demonstrated after endometrioma excision as assessed by decreased AMH levels and antral follicle counts.8-10 Busacca et al. reported 2.4% rate of premature ovarian failure immediately after bilateral endometrioma surgery.21 Such a report is alarming, since bilateral lesions account for 19%–28% in patients with ovarian endometriosis.22 Coccia et al. have also shown that in women previously subjected to bilateral endometrioma removal, the mean age at menopause is...
significantly lower.\textsuperscript{23} Factors shown to influence ovarian reserve after surgery are the expertise of the surgeon, the size of the cyst, and the composition of the cyst wall.\textsuperscript{10,24} Yu et al. showed a significantly diminished antral follicle count in the hands of an inexperienced surgeon for both unilateral and bilateral cystectomies.\textsuperscript{30} Romualdi et al. showed that the smaller cysts and fibroblastic capsular types were more associated with the follicles being removed during surgery, likely due to less demarcated cleavage plane.\textsuperscript{24} In such patients, de-roofing and ablation is the preferred procedure to minimize follicular loss.

The effect of ovarian surgery on ovarian response to fertility medications is subject to a matter of debate. Criteria for poor ovarian response include small numbers of developed follicles or retrieved oocytes, and low estradiol (E2) levels.\textsuperscript{25} Our study showed no difference in the overall ovarian responses among the three populations studied. In two of such populations studied (group 2 and group 3), excision of endometrioma was not performed. Therefore, our data suggest that excision of endometrioma does not affect ovarian response to fertility medications. Similarly, Canis et al. in a retrospective study showed that in the hands of an experienced surgeon there was no significant reduction in the number of oocytes retrieved.\textsuperscript{25} In addition, in a retrospective study of women with severe endometriosis who underwent laparoscopic vaporization of the cyst wall, Donnez et al. showed that in women with unilateral endometriomas undergoing excision there was a similar ovarian response in cystectomized ovaries when compared with the contralateral nonoperated ovary.\textsuperscript{26} In a Cochrane review in 2008, Hart et al. showed that an increased ovarian response with excisional procedures than with ablative procedures for endometrioma removal in women undergoing IVF.\textsuperscript{18} On the other hand, several retrospective studies have reported reduced responses to gonadotrophins after endometrioma excision.\textsuperscript{27–31} Such discrepancy in the literature can be related to the experience of the surgeon and other surgical factors such as the nature of cyst, the baseline ovarian reserve in some patients, and surgical technique as mentioned earlier.

Our study showed that the mean total dose of gonadotropin administered in IVF-ET cycle I was higher (p=0.03) in patients who underwent endometrioma excision. This could be related to an element of decrease ovarian reserve secondary to surgery and is consistent with existing studies. However, such differences were not seen in the second cycle, probably due to the smaller sample size (group 1: n=8, group 2: n=14 and group 3: n=26). Similarly, other investigators have reported higher gonadotrophin dose after endometrioma excision surgery in women undergoing IVF.\textsuperscript{32–34}

Our study showed a statistically significant increase in pregnancy rate per cycle in the endometrioma group (69.7%) versus in the ovariolysis group (48.1%) and tubal factor group (48.0%). The delivery rates per cycle and per patient were not significantly different among the three groups. This could be explained by the statistically significant increase in miscarriage rate in the endometrioma group (39.1%) versus the ovariolysis group (11.5%) and tubal factor group (14.3%). Similar to our overall results, In a retrospective study of women with severe endometriosis who underwent laparoscopic vaporization of the cyst wall, Donnez et al. showed similar IVF outcomes when compared with women having tubal infertility.\textsuperscript{26} However, the effect of ovarian surgery on pregnancy rates in women undergoing IVF-ET is still a matter of debate. In a randomized controlled trial, Demirol et al. showed that ovarian surgery in women undergoing IVF treatment did not affect the fertilization, implantation, and pregnancy rates.\textsuperscript{33} Similarly, Garcia-Velasco et al. showed that previous endometrioma excision surgery in women undergoing IVF did not improve the number of oocytes retrieved, number of embryos obtained/transferred, and the pregnancy rates.\textsuperscript{34,35} Yu et al. showed better live birth rates when experienced laparoscopic surgeons treated endometriomas in women undergoing IVF.\textsuperscript{10} In a Cochrane review, Hart et al. showed that removal of endometriomas were associated with a significant increase of spontaneous pregnancy in subfertile women.\textsuperscript{18} The association between endometriosis and an increased risk of spontaneous miscarriage is also a topic of debate. There have been retrospective studies in the past that have shown an increased risk of pregnancy loss with endometriosis.\textsuperscript{36–38} These studies lacked control groups. More recent studies have refuted this and shown no causal relationship.\textsuperscript{39,40} Our study showed an increased miscarriage rate in the endometrioma excision group in comparison to the ovariolysis group, although patients in both groups had stage III/VI endometriosis. In addition, our data suggest higher miscarriage rate in the endometrioma excision group compared with the tubal factor group. More research in needed to evaluate the possible association between miscarriage and some patients with endometriosis, especially after IVF treatment.
Our study has some limitations as a result of its retrospective nature with the inherent biases that are associated with such design and its sample size, which may limit its generalizability. One area of strength is there were no significant differences in age, duration of infertility, or the type of infertility between the three populations studied. Another area of strength in our study is the fact that all surgeries were performed using the same technique. In addition, during IVF-ET, all COS and ETs were performed by only two physicians (Mostafa I. Abuzeid and Mohammed Ashraf), which limit confounding factors that may affect implantation rates and, in turn, pregnancy outcomes. Our study compared the study group (patients who had endometrioma excision) with another group of patients with the same stage of endometriosis except that they had no endometrioma. This may have controlled for some confounding factors related to endometriosis, whereas most existing studies have only tubal factor infertility as the control group.

Conclusion

Our study suggests that excision of endometrioma in patients with advanced endometriosis before IVF-ET treatment does not compromise the overall ovarian reserve or pregnancy outcomes. Large, prospective, and randomized controlled trials are still required to shed more light on this matter.

Acknowledgments

The authors would like to acknowledge the Hurley Research Department for helping them with the statistical analysis of their data. They would also like to acknowledge Cheryl Anderson for helping them prepare this article.

Disclosure Statement

No competing financial interests exist.

References

27. Pagidas K, Falcone T, Hemmings R, Miron P. Comparison of reoperation for moderate (stage III) and severe (stage IV) endometriosis-related infertility with in vitro fertilization-embryo transfer. Fertil Steril 1996;65:791.
35. Garcia-Velasco JA, Somigliana E. Management of endometriomas in women requiring IVF: To touch or not to touch. Hum Reprod 2009;24:496.

Address correspondence to:
Rubin Raju, MD
Department of Obstetrics and Gynecology
Hurley Medical Center
Michigan State University
College of Human Medicine
Flint Campus
Flint, MI 48503
E-mail: rraju1@hurleymc.com